Print page content Print
Increase text size Decrease text size
Text Size

VANGUARD® CIV H3N2/H3N8 (25 x 1DS)

Vanguard CIV H3N2 H3N8

The VANGUARD® CIV H3N2/H3N8 vaccine protects dogs against both H3N2 and H3N8 strains of canine influenza virus (CIV), which can be highly contagious among dogs.

Expand All
    • A bivalent canine flu vaccine for protection against both highly contagious H3N2 and H3N8 strains of canine influenza virus (CIV)

    • Demonstrated safety and efficacy1,2

    • Helps to reduce or prevent clinical signs of CIV infection, pathological lung lesions attributable to CIV infection and CIV infections of lungs and trachea1,3

    • No significant adverse events attributed to vaccination observed2

    • Helping protect your canine patients can also help protect dogs in your community

    • Covered by the Companion Animal Immunization Support Guarantee

  • Directions: Vaccination of healthy dogs is recommended. Shake well. Aseptically administer 1 mL subcutaneously. Healthy dogs 8 weeks of age and older should receive 2 doses administered 3 weeks apart. Annual revaccination has not been established for this product.


    1. Data on file, Study Report No. B862R-US-16-226, Zoetis Inc.

    2. Data on file, Study Report No. B961R-US-16-225, Zoetis Inc.

    3. Data on file, Study Report No. 3161R-60-09-383, Zoetis Inc.

Precautions: Store at 2°-7°C (35°-45°F). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Contains gentamicin as preservative.

Technical inquiries should be directed to Zoetis Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only.




We are Mon–Fri, 8am–8pm ET

email to

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2019 Zoetis Services LLC. All rights reserved.